Prove Your Drug Caused SJS: A California Case Playbook

1) The core proof question

In California drug-injury litigation, causation is usually the centerpiece: connecting (1) the SJS/TEN diagnosis to (2) a particular medication, and then (3) tying that medication to a legally actionable theory (often failure to warn). Clinically, SJS/TEN is widely described as a severe, often medication-related mucocutaneous reaction and a medical emergency. MedlinePlus overview.

Because SJS/TEN can be associated with medications and also occur in other clinical contexts, stronger cases typically work through timing, alternative explanations, and what was known about risk for the product at the relevant time.

2) Lock down the timeline (often the strongest factual backbone)

SJS/TEN cases often hinge on chronology. Attorneys and medical experts commonly build a day-by-day sequence showing medication starts/stops, dose changes, early symptoms, rash progression, mucosal involvement, and hospitalization/transfer dates. Early symptoms can include fever and sore throat before skin findings, and prompt care is critical. MedlinePlus (SJS/TEN symptoms).

3) Confirm the diagnosis with objective medical records

Defendants may dispute diagnosis (for example, arguing another drug eruption or infection-related rash). Records that commonly matter include dermatology consults and differentials, pathology/biopsy reports (if performed), ophthalmology findings, burn/ICU documentation, and discharge summaries listing suspected culprit drug(s). See StatPearls: Stevens-Johnson Syndrome.

4) Identify the likely culprit drug(s) and competing causes

Causation is often comparative: why Drug A is more likely than Drug B (or an infection) to have triggered the reaction, given exposures and timing. Many clinical references emphasize that medications are a common trigger and that careful medication history is central. StatPearls (etiology and evaluation).

• All medications in the relevant window (prescription, OTC, supplements).
• New starts versus long-term maintenance drugs (new exposures are often scrutinized).
• Recent infections and other potential triggers documented in the chart.
• Any documented re-exposure (if it occurred inadvertently). Re-challenge is dangerous and should never be attempted.

5) Experts: general causation and specific causation

In contested pharmaceutical cases, plaintiffs commonly use experts to address (1) whether the drug is capable of causing the injury in humans (general causation) and (2) whether it caused the injury in the individual patient (specific causation), often using differential etiology. California courts require trial judges to act as gatekeepers against speculative expert opinions. Sargon Enterprises, Inc. v. Univ. of S. Cal. (2012) 55 Cal.4th 747.

6) California liability theories commonly asserted (fact-dependent)

Common legal theories include failure to warn and negligence. In California, manufacturers of prescription drugs have a duty to warn about known or knowable risks, and warning issues frequently focus on communications to prescribing physicians (often discussed under the learned intermediary doctrine). Carlin v. Superior Court (1996) 13 Cal.4th 1104.

Design-defect strict liability claims involving prescription drugs can be more constrained under California law and are highly fact-dependent. Brown v. Superior Court (1988) 44 Cal.3d 1049.

• Failure to warn: alleged inadequacy in labeling, risk communications, or instructions (including early symptom response guidance).
• Manufacturing defect: deviation from specifications (requires technical proof and, when possible, product/lot evidence).
• Negligence: unreasonable conduct in testing, surveillance, marketing, or risk communication.

7) Warning causation: would a better warning likely have changed outcomes?

Even if a drug is capable of causing SJS/TEN, a key dispute in warning-based cases is often whether a different warning would likely have changed prescribing decisions, monitoring, or patient action in time to prevent or mitigate harm. The physician’s role is commonly central to that analysis. Carlin.

Evidence used to evaluate this issue may include prescriber testimony, contemporaneous charting of counseling and informed consent, historical label language, and what risk signals were reasonably available at the time.

8) Damages: document the full medical and life impact

SJS/TEN can involve prolonged hospitalization and significant long-term sequelae (including ocular complications). Clinical references describe potentially severe complications and long-term effects. MedlinePlus; StatPearls.

• Itemized billing and insurance EOBs plus full medical records.
• Symptom/function journal and follow-up care documentation.
• Employment and wage records (missed work and job impact).
• Photographs over time (healing, scarring, ocular changes when appropriate).

9) Checklist: preserve these records and materials now

Medical safety note: do not stop or start prescription medications without medical guidance. If SJS/TEN is suspected, seek emergency care.

10) What to expect procedurally in California (high-level)

Pharmaceutical injury cases commonly involve pre-suit investigation and record review, filing in the proper court, discovery (including prescriber and expert depositions), and expert admissibility motion practice. California’s personal-injury limitations period is commonly two years, but accrual and tolling can be fact-specific (including discovery-rule issues). Code Civ. Proc. Section 335.1; Jolly v. Eli Lilly & Co. (1988) 44 Cal.3d 1103.

If you want help evaluating preservation steps, potential defendants, or timing, contact us.

FAQ

How do I prove which drug caused SJS/TEN if I took more than one medication?

Proof often comes from a medication timeline, clinical presentation, and expert differential etiology that compares likely triggers, including infections and other exposures, and explains why one drug is more probable than alternatives.

Do I need a biopsy to prove SJS/TEN?

Not always, but dermatology documentation, hospital course records, and any pathology that exists can help support the diagnosis and address defense arguments about alternative rashes.

What matters most in a California failure-to-warn theory?

Common disputes include what the manufacturer knew or should have known, what the label said at the time, and whether a different warning would likely have changed prescribing, counseling, or patient actions.

What should I do first if I am considering a claim?

Prioritize medical care, then preserve medication packaging and pharmacy histories, gather complete medical records, and speak with a California attorney about deadlines and next steps.

Disclaimer (California)

This article is for general informational purposes only and does not constitute legal advice or create an attorney-client relationship. SJS/TEN drug-injury matters are highly fact-specific, and California filing deadlines and substantive rules can vary based on the facts, parties, and claims. Do not rely on this article as a substitute for advice from a qualified California attorney about your specific situation.

Call to action: For help with records preservation and a case-specific evaluation, contact us.